Literature DB >> 32864776

Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.

Laura Loman1, Gilles F H Diercks2, Marie L A Schuttelaar1.   

Abstract

Entities:  

Keywords:  dupilumab; hand dermatitis; hand eczema; hyperkeratotic hand eczema; treatment

Year:  2020        PMID： 32864776      PMCID： PMC7891406          DOI： 10.1111/cod.13693

Source DB:  PubMed          Journal:  Contact Dermatitis        ISSN： 0105-1873            Impact factor:   6.600


× No keyword cloud information.
  15 in total

1.  A Retrospective Review of Dupilumab for Hand Dermatitis.

Authors:  Nicole Lee; Naina Chipalkatti; Pedro Zancanaro; Courtney Kachuk; Nicole Dumont; David Rosmarin
Journal:  Dermatology       Date:  2019-02-06       Impact factor: 5.366

2.  Construction and validation of a photographic guide for assessing severity of chronic hand dermatitis.

Authors:  P J Coenraads; H Van Der Walle; K Thestrup-Pedersen; T Ruzicka; B Dreno; C De La Loge; M Viala; S Querner; T Brown; M Zultak
Journal:  Br J Dermatol       Date:  2005-02       Impact factor: 9.302

3.  Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis.

Authors:  Emma Guttman-Yassky; Robert Bissonnette; Benjamin Ungar; Mayte Suárez-Fariñas; Marius Ardeleanu; Hitokazu Esaki; Maria Suprun; Yeriel Estrada; Hui Xu; Xiangyu Peng; Jonathan I Silverberg; Alan Menter; James G Krueger; Rick Zhang; Usman Chaudhry; Brian Swanson; Neil M H Graham; Gianluca Pirozzi; George D Yancopoulos; Jennifer D D Hamilton
Journal:  J Allergy Clin Immunol       Date:  2018-09-05       Impact factor: 10.793

4.  Severe treatment-resistant acute and recurrent vesicular chronic hand eczema successfully treated with dupilumab.

Authors:  Anne-Sofie Halling; Claus Zachariae; Jacob P Thyssen
Journal:  Contact Dermatitis       Date:  2020-03-19       Impact factor: 6.600

5.  Dupilumab for the treatment of dyshidrotic eczema in 15 consecutive patients.

Authors:  Reid A Waldman; Madeline E DeWane; Brett Sloan; Jane M Grant-Kels; Jun Lu
Journal:  J Am Acad Dermatol       Date:  2020-01-08       Impact factor: 11.527

6.  The hand eczema proteome: imbalance of epidermal barrier proteins.

Authors:  S Molin; J Merl; K A Dietrich; M Regauer; M Flaig; V Letulé; T Saucke; T Herzinger; T Ruzicka; S M Hauck
Journal:  Br J Dermatol       Date:  2015-02-26       Impact factor: 9.302

7.  Validation of the Dutch Quality of Life in Hand Eczema Questionnaire (QOLHEQ).

Authors:  J A F Oosterhaven; R F Ofenloch; M L A Schuttelaar
Journal:  Br J Dermatol       Date:  2019-11-24       Impact factor: 9.302

8.  Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study.

Authors:  Jart A F Oosterhaven; Angelique N Voorberg; Geertruida L E Romeijn; Marjolein S de Bruin-Weller; Marie L A Schuttelaar
Journal:  J Dermatol       Date:  2019-06-12       Impact factor: 4.005

9.  Dupilumab for occupational irritant hand dermatitis in a nonatopic individual: A case report.

Authors:  Gefei Alex Zhu; Golara Honari; Justin M Ko; Albert S Chiou; Jennifer K Chen
Journal:  JAAD Case Rep       Date:  2020-03-25

10.  Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.

Authors:  Laura Loman; Gilles F H Diercks; Marie L A Schuttelaar
Journal:  Contact Dermatitis       Date:  2020-10-01       Impact factor: 6.600
View more
  3 in total

Review 1.  Irritant Contact Dermatitis - a Review.

Authors:  Kajal Patel; Rosemary Nixon
Journal:  Curr Dermatol Rep       Date:  2022-04-07

2.  Three cases of non-atopic hyperkeratotic hand eczema treated with dupilumab.

Authors:  Laura Loman; Gilles F H Diercks; Marie L A Schuttelaar
Journal:  Contact Dermatitis       Date:  2020-10-01       Impact factor: 6.600

3.  The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry.

Authors:  Angelique N Voorberg; Geertruida L E Romeijn; Marjolein S de Bruin-Weller; Marie L A Schuttelaar
Journal:  Contact Dermatitis       Date:  2022-04-24       Impact factor: 6.419
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.